Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma Article (Faculty180)

cited authors

  • Singla, Nirmish; Christie, Alana; Freifeld, Yuval; Ghandour, R A; Woldu, So L; Clinton, Timothy N; Petros, Firas G; Robyak, Haley; Yeh, Hsin- C; Fang, Dong; Enikeev, Dmitry; Bagrodia, Aditya; Sagalowsky, Arthur I; Lotan, Yair; Raman, Jay D; Matin, Surena F; Margulis, Vitaly

description

  • Whether pathologic stage at radical nephroureterectomy (RNU) can serve as an appropriate surrogate for oncologic outcomes in patients with high-grade (HG) upper tract urothelial carcinoma (UTUC) treated with neoadjuvant chemotherapy (NAC) is not defined. We sought to determine whether patients who achieve pathologically non-muscle-invasive (ypT0, ypTa, ypT1, ypTis) HG UTUC after receipt of NAC exhibit oncologic outcomes comparable to those who are inherently low stage without chemotherapy.

authors

publication date

  • 2020

published in

start page

  • 933.e7

end page

  • 933.e12

volume

  • 38